Ha ha flailing about pulling $900m per annum from one product which is heading for $1.5b at least. Another two products about to be approved which will add another $1.5b.
European and other jurisdiction approvals about to drop.
A prostate therapy product in ph3 which has been seen to give 3× the overall survival of the only approved product.
Many other things happening too...
That's some handy flailing about.
CU6 Price at posting:
$3.76 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)